PATENTSCOPE: EN_ALL:nmr AND PA:valeant

DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANIILIDES AS POTASSIUM CHANNEL MODULATORS (Fri, 05 Aug 2011)
This invention provides a compound of formula IA where X = 0 or S; Y is 0 or S; q = 1 or 0; and other substituents are defined herein. Such compounds can affect the opening of, or otherwise modulate, voltage-gated potassium channels. Such compounds useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.
>> Read More

BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS (Fri, 22 Jan 2010)
The present invention relates to benzyloxyanilide derivatives having the following structural formula (I): The compounds of the present invention are useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.
>> Read More

DERIVATIVES OF 5-AMINO-4, 6-DISUBSTITUTED INDOLE AND 5-AMINO-4,6-DISUBSTITUTED INDOLINE AS POTASSIUM CHANNEL MODULATORS (Fri, 20 Feb 2009)
This invention provides compounds of formula I where the dashed line represents an optional double bond; where R1 is phenyl, naphthyl, pyridyl, pyrimidyl, pyrrolyl, imidazolyl, pyrazyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, optionally substituted, and other substituents are defined herein. Such compounds are potassium channel modulators.
>> Read More

NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS (Fri, 06 Feb 2009)
This invention provided compounds of formula (I), where W and Z are, independently, CH or N, and where other substituents are defined herein. Such compounds are potassium channel modulators. The invention also provides a composition comprising a pharmaceutically acceptable carrier or excipient and at least one of the following: a pharmaceutically effective amount of a compound of formula (I); a pharmaceutically acceptable salt of a compound of formula (I); a pharmaceutically acceptable ester of a compound of formula (I). The invention also provides a method of preventing or treating a disease or disorder which is affected by activities of potassium channels, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a salt or ester or solvate thereof.
>> Read More

3-HYDROXYISOTHIAZOLE-4-CARBOXAMIDINE DERIVATIVES AS CHK2 INHIBITORS (Thu, 25 Dec 2008)
This invention provides compounds of Formula (I), which are inhibitors of Chk2 and are useful as a radiation protection agents in anticancer radiotherapy. A method of modulating Chk2 in vitro includes treating a substrate with Chk2 in the presence of compounds of formula I. A method of making a compound of formula I includes: a) forming a biaryl amine having an amino (NH2) group; b) converting the amino group to an isothiocyanate group; c) adding a cyanoacetamide to said isothiocyanate group to form a thioamide adduct; d) cyclizing said thioamide adduct to form an isothiazole having a cyano group; and e) adding an amine to said cyano group to form a carboxamidine group.
>> Read More

DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS (Thu, 25 Dec 2008)
This invention provides potassium channel modulators which are compounds of formula (I), (formula I), where at least one of W and Z is N; where the moiety (formula II), is one of Groups A or B below (formula A), where Ar is a 1,2-fused, six membered ring aromatic group, bearing substituents R1 and R2 as defined below, and containing zero or one ring nitrogen atom; and where other substituents are defined herein. The invention also provides a composition comprising a pharmaceutically acceptable carrier and at least one of the following: i) a pharmaceutically effective amount of a compound of formula I and ii) a pharmaceutically acceptable salt, ester, or prodrug thereof. The invention also provides a method of preventing or treating a disease or disorder which is affected by activities of potassium channels, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I or a salt, ester, or prodrug thereof.
>> Read More

1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS (Fri, 06 Jun 2008)
This invention is directed to compounds of formula (I), where G is -O-, -S-, -C(g1)(g2)-, or -NH-, and n = 1, 2, or 3. Such compounds modulate potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders which are affected by modulation of potassium ion channels. One such condition is seizure disorders.
>> Read More

DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS (Fri, 29 Feb 2008)
This invention provides a compound of formula (IA) where X = O or S; Y is O or S; q = 1 or 0; and other substituents are defined herein. Such compounds can affect the opening of, or otherwise modulate, voltage-gated potassium channels. They are potentially useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.
>> Read More

3', 5' - CYCLIC NUCLEOSIDE ANALOGUES FOR TREATMENT OF HCV (Fri, 09 Mar 2007)
This invention provides compounds according to formula (I) where B is a 6-membered monocyclic nitrogen-containing heteroaryl group or a 5 + 6 fused bicyclic nitrogen-containing heteroaryl group, and A is selected from Groups (1), (2), (3), and (4) where Groups (1), (2), (3), and (4), are defined herein. These compounds are useful in the treatment of Hepatitis C infection.
>> Read More

PHENYLAMINO ISOTHIAZOLE CARBOXAMIDINES AS MEK INHIBITORS (Fri, 15 Dec 2006)
The invention concerns compounds of formula (I) which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted- 3-hydroxy-5- arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)- ones.
>> Read More

PHOSPHORAMIDATE PRODRUGS FOR TREATMENT OF VIRAL INFECTION (Fri, 17 Nov 2006)
The invention concerns 2'-methyl ribonucleotide phosphoramidates which are neutral prodrugs which are converted in vivo to 2'- methyl ribonucleotide triphosphates. These compounds are useful in the treatment of viral infection. Of particular interest are prodrugs of a methylsulfonylhydrazinyl purine 2'-methyl nucleotide triphosphate: 2'methyl- N6-alkyl-N6- (N-methylsulfonamide) adenosine triphosphate and its 2-amino derivative.
>> Read More

6-HYDRAZINOPURINE 2'-METHYL RIBONUCLEOSIDES AND NUCLEOTIDES FOR TREATMENT OF HCV (Fri, 17 Nov 2006)
Compounds of formula I, are provided, which are useful as inhibitors of hepatitis C virus.
>> Read More